Project Grant R01CA288753
Award Date
12/11/24
Completion Date
11/30/29
Dollars Obligated
$634K
Federal Agency
National Cancer Institute
Awardee
Mayo Clinic (Y2K4F9RPRRG7)
Federal Grant Program
93.395
Assistance Type
Project Grant
Place of Performance
Rochester, MN 55905, USA
Similar Awards
This Project Grant award from the National Cancer Institute (CFDA 93.393 - Cancer Cause and Prevention Research) is funding a $1,456,062 research project at the Mayo Clinic to investigate the impact of chromosomal instability on prostate cancer aggressiveness. The key objectives are to: 1) identify the substrates and cofactors by which the MASTL kinase regulates new functions in high chromosomal instability prostate cancer, 2) explore the molecular mechanisms underlying chromosomal...
The National Cancer Institute (NCI) awarded a $205,700 Project Grant (CFDA 93.395 - Cancer Treatment Research) to the Sloan-Kettering Institute for Cancer Research to evaluate how intrinsic tumor features modulate the development of resistance to targeted therapies in colorectal cancer. The research aims to explore a novel combination approach of DNA repair inhibition and targeted therapy to prevent the emergence of resistance. Through analysis of clinical samples, cell lines, and...
This Project Grant award from the National Cancer Institute (CFDA 93.393 - Cancer Cause and Prevention Research) will provide $582,198 to Northwestern University from Jul 12, 2024 to Jun 30, 2029 to conduct research on the role of the EZH2 protein in regulating PARP1 function and PARP inhibitor resistance in prostate cancer. The research aims to identify how EZH2-mediated PARP1 methylation impacts DNA damage repair and transcription activity, with the goal of developing new EZH2 and PARP1...
The federal Project Grant award titled "TOWARDS CHARACTERIZATION OF EPIGENETIC TARGETS IN PROSTATE CANCER" is funded by the National Cancer Institute (NCI) under the Cancer Cause and Prevention Research (CFDA 93.393) program. The $371,719 award, spanning March 1, 2025 to February 28, 2030, will support research conducted by The Trustees of the University of Pennsylvania to gain deeper molecular insights into how the epigenetic regulator NSD2 influences the chromatin landscape and AR...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $421,042 to The Johns Hopkins University to conduct a study on IDH1-mutant prostate cancer. The primary objectives are to investigate the molecular mechanisms that prevent therapy resistance in this rare cancer subtype and identify novel therapeutic targets to improve treatment outcomes. The research approach involves three key activities: 1) conducting a comprehensive clinical,...
This federal Project Grant award from the National Cancer Institute (CFDA 93.398 - Cancer Research Manpower) provides $238,722 to the Sloan-Kettering Institute for Cancer Research to investigate the role of mutagenic DNA repair in the persistence of cancer cells and the development of acquired drug resistance. The key objectives are to: (1) examine persistence mechanisms in response to PARP inhibitor treatment in BRCA1/2-mutant cancer cells, (2) explore the role of the mutagenic DNA repair...
The National Cancer Institute (NCI) awarded a $487,393 Project Grant under the Cancer Cause and Prevention Research (CFDA 93.393) program to the Sloan-Kettering Institute for Cancer Research in New York, NY. The grant funding will support research to determine the role of key proteins like RAD52, HELQ, and POLQ in backup DNA double-strand break repair pathways in homologous recombination deficient (HRD) cancers. The objective is to better understand these alternative repair mechanisms and...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $415,902 to the University of Massachusetts Boston to conduct research aimed at overcoming treatment resistance in castration-resistant prostate cancer. The key focus is on understanding how the transcription factor FOXA2, in collaboration with the AP-1 transcription factor complex, drives lineage plasticity and multilineage transitions in prostate cancer cells. The research will...
The National Cancer Institute (NCI) awarded a $553,550 Project Grant (CFDA 93.395 Cancer Treatment Research) to Cedars-Sinai Medical Center for a translational study on a synthetic lethality interaction between CD105 and androgen receptor signaling for castration-resistant prostate cancer patients. The goal is to better understand a novel signaling axis initiated in prostate cancer patients by next-generation androgen receptor signaling inhibitors (ARSIs), which can lead to therapeutic...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) to the Sloan-Kettering Institute for Cancer Research will support a $583,973.00 research project over a 5-year period from January 1, 2025 to December 31, 2029. The research aims to investigate the role of EP300 gene mutations in bladder cancer pathogenesis and drug resistance, with a focus on understanding how EP300 loss-of-function mutations impact response to the FGFR inhibitor erdafitinib....